LIR Life Sciences Finalizes Study Design for Evaluating Transdermal Agents

LIR Life Sciences Corp. has announced the completion of a study design aimed at assessing the capability of novel transdermal agents to facilitate the penetration of therapeutic macromolecules through the skin. Employing full-thickness porcine skin, considered a relevant model for human skin, the study will evaluate molecules ranging from 5kDa to approximately 150kDa, using confocal microscopy and fluorescence-based measurements.

The experimental framework, developed in collaboration with scientific partners, will test transdermal agent-containing formulations against controls lacking these agents. The study aims to determine if these agents can improve the movement of large molecules through the skin and potentially replace injections for delivering certain therapies.

The design phase completion allows LIR to advance towards study execution expected in early 2026, with results set to inform new skin-applied, needle-free therapeutic delivery strategies.